IPSEN (IPN.PA) Stock Fundamental Analysis
Europe - EPA:IPN - FR0010259150 - Common Stock
119 EUR
-0.6 (-0.5%)
Taking everything into account, IPN scores 6 out of 10 in our fundamental rating. IPN was compared to 50 industry peers in the Pharmaceuticals industry. IPN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IPN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year IPN was profitable.
IPN had a positive operating cash flow in the past year.
In the past 5 years IPN has always been profitable.
Each year in the past 5 years IPN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of IPN (6.56%) is comparable to the rest of the industry.
The Return On Equity of IPN (10.59%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 14.88%, IPN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for IPN is in line with the industry average of 14.78%.
The 3 year average ROIC (12.97%) for IPN is below the current ROIC(14.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROIC | 14.88% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
1.3 Margins
IPN has a Profit Margin of 11.91%. This is comparable to the rest of the industry: IPN outperforms 54.00% of its industry peers.
IPN's Profit Margin has declined in the last couple of years.
IPN has a Operating Margin of 26.01%. This is in the better half of the industry: IPN outperforms 74.00% of its industry peers.
IPN's Operating Margin has declined in the last couple of years.
IPN has a better Gross Margin (83.32%) than 88.00% of its industry peers.
IPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.01% | ||
| PM (TTM) | 11.91% | ||
| GM | 83.32% |
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IPN is creating value.
Compared to 1 year ago, IPN has more shares outstanding
IPN has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for IPN has been reduced compared to a year ago.
2.2 Solvency
IPN has an Altman-Z score of 4.44. This indicates that IPN is financially healthy and has little risk of bankruptcy at the moment.
IPN has a better Altman-Z score (4.44) than 70.00% of its industry peers.
IPN has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.69, IPN belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
IPN has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.20, IPN is doing good in the industry, outperforming 76.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 4.44 |
ROIC/WACC1.96
WACC7.6%
2.3 Liquidity
IPN has a Current Ratio of 1.98. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
IPN's Current ratio of 1.98 is fine compared to the rest of the industry. IPN outperforms 74.00% of its industry peers.
IPN has a Quick Ratio of 1.80. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
IPN has a Quick ratio of 1.80. This is amongst the best in the industry. IPN outperforms 84.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
IPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.24%, which is quite good.
Measured over the past years, IPN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.79% on average per year.
IPN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.45%.
IPN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.83% yearly.
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%44.4%
Revenue 1Y (TTM)9.45%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%9.67%
3.2 Future
Based on estimates for the next years, IPN will show a small growth in Earnings Per Share. The EPS will grow by 5.16% on average per year.
Based on estimates for the next years, IPN will show a small growth in Revenue. The Revenue will grow by 4.89% on average per year.
EPS Next Y1.38%
EPS Next 2Y3.24%
EPS Next 3Y4.35%
EPS Next 5Y5.16%
Revenue Next Year6.79%
Revenue Next 2Y5.81%
Revenue Next 3Y6.09%
Revenue Next 5Y4.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.59, the valuation of IPN can be described as reasonable.
IPN's Price/Earnings ratio is a bit cheaper when compared to the industry. IPN is cheaper than 74.00% of the companies in the same industry.
IPN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.30.
A Price/Forward Earnings ratio of 10.87 indicates a reasonable valuation of IPN.
72.00% of the companies in the same industry are more expensive than IPN, based on the Price/Forward Earnings ratio.
IPN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.59 | ||
| Fwd PE | 10.87 |
4.2 Price Multiples
96.00% of the companies in the same industry are more expensive than IPN, based on the Enterprise Value to EBITDA ratio.
64.00% of the companies in the same industry are more expensive than IPN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.34 | ||
| EV/EBITDA | 5.64 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IPN does not grow enough to justify the current Price/Earnings ratio.
IPN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)8.37
PEG (5Y)1.32
EPS Next 2Y3.24%
EPS Next 3Y4.35%
5. Dividend
5.1 Amount
IPN has a Yearly Dividend Yield of 1.17%. Purely for dividend investing, there may be better candidates out there.
IPN's Dividend Yield is comparable with the industry average which is at 3.06.
Compared to an average S&P500 Dividend Yield of 2.45, IPN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.17% |
5.2 History
The dividend of IPN has a limited annual growth rate of 3.72%.
Dividend Growth(5Y)3.72%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
25.90% of the earnings are spent on dividend by IPN. This is a low number and sustainable payout ratio.
The dividend of IPN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.9%
EPS Next 2Y3.24%
EPS Next 3Y4.35%
EPA:IPN (9/12/2025, 7:00:00 PM)
119
-0.6 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.53%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap9.97B
Analysts70
Price Target128.52 (8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.17% |
Yearly Dividend1.2
Dividend Growth(5Y)3.72%
DP25.9%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.59%
PT rev (3m)0.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.39%
EPS NY rev (3m)-0.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.59 | ||
| Fwd PE | 10.87 | ||
| P/S | 2.65 | ||
| P/FCF | 19.34 | ||
| P/OCF | 11.12 | ||
| P/B | 2.36 | ||
| P/tB | 7.47 | ||
| EV/EBITDA | 5.64 |
EPS(TTM)10.27
EY8.63%
EPS(NY)10.95
Fwd EY9.2%
FCF(TTM)6.15
FCFY5.17%
OCF(TTM)10.71
OCFY9%
SpS44.86
BVpS50.46
TBVpS15.93
PEG (NY)8.37
PEG (5Y)1.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROCE | 18.07% | ||
| ROIC | 14.88% | ||
| ROICexc | 20.46% | ||
| ROICexgc | 77.25% | ||
| OM | 26.01% | ||
| PM (TTM) | 11.91% | ||
| GM | 83.32% | ||
| FCFM | 13.72% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
ROICexc(3y)20.33%
ROICexc(5y)25.52%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)15.75%
ROCE(5y)18.64%
ROICexcg growth 3Y-59.92%
ROICexcg growth 5Y-22.83%
ROICexc growth 3Y-29.05%
ROICexc growth 5Y-11.89%
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.5 | ||
| Cap/Depr | 55.54% | ||
| Cap/Sales | 10.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 53.9% | ||
| Profit Quality | 115.14% | ||
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 4.44 |
F-Score7
WACC7.6%
ROIC/WACC1.96
Cap/Depr(3y)131.36%
Cap/Depr(5y)124.73%
Cap/Sales(3y)11.81%
Cap/Sales(5y)11.18%
Profit Quality(3y)85.87%
Profit Quality(5y)89.99%
High Growth Momentum
Growth
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%44.4%
EPS Next Y1.38%
EPS Next 2Y3.24%
EPS Next 3Y4.35%
EPS Next 5Y5.16%
Revenue 1Y (TTM)9.45%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%9.67%
Revenue Next Year6.79%
Revenue Next 2Y5.81%
Revenue Next 3Y6.09%
Revenue Next 5Y4.89%
EBIT growth 1Y66.72%
EBIT growth 3Y-6.06%
EBIT growth 5Y1.3%
EBIT Next Year27.18%
EBIT Next 3Y13.1%
EBIT Next 5Y7.52%
FCF growth 1Y-33.64%
FCF growth 3Y-35.67%
FCF growth 5Y-17.46%
OCF growth 1Y-8.92%
OCF growth 3Y-0.07%
OCF growth 5Y7.84%